Loading chat...

NJ A1405

Bill

Status

Introduced

1/9/2024

Primary Sponsor

Shama Haider

Click for details

Origin

General Assembly

2024-2025 Regular Session

AI Summary

  • Pharmacists are prohibited from interchanging any anti-epileptic drug or formulation (brand to generic, generic to brand, or between manufacturers) for treating seizures without prior notification and signed informed consent from both the prescribing physician and the patient (or parent, guardian, or spouse)

  • "Interchange" encompasses substituting generic for brand, brand for generic, different generic manufacturers, different formulations, or different anti-epileptic products than originally prescribed

  • The bill addresses concerns that small variations in drug concentrations between FDA-equivalent rated medications can cause toxic effects or breakthrough seizures in epilepsy patients

  • Takes effect on the first day of the second month following enactment

  • Supplements existing pharmacy law (P.L.1977, c.240) governing drug substitution practices

Legislative Description

Prohibits substitution of prescribed epilepsy drugs by pharmacists without prior notification to and written consent of physician and patient.

Health

Last Action

Introduced, Referred to Assembly Health Committee

1/9/2024

Committee Referrals

Health1/9/2024

Full Bill Text

No bill text available